LivingGLP1
Study S002414

Finerenone Research of Outcomes and Drug Utilization

ClinicalTrials.gov record

Registration

Registration
NCT06278207
Acronym
FINEROD
Study type
OBSERVATIONAL
Status
RECRUITING
Enrollment
50000
Start
2024-05-15
Primary completion
2026-09-30
Lead sponsor
Bayer
Conditions
Chronic Kidney Disease; Type 2 Diabetes Mellitus
Interventions
DRUG:Finerenone (BAY 94-8862)
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Participants' characteristics at baseline in a cohort of participants with CKD and T2D who initiate finerenone. [12 months before first prescription/dispensation of finerenone (index date)]
  • Participants' comorbidities at baseline in a cohort of participants with CKD and T2D who initiate finerenone. [12 months before first prescription/dispensation of finerenone (index date)]
  • Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone. [12 months before first prescription/dispensation of finerenone (index date)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0009220Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan-A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform.
Sato A, Journal of clinical medicine
2024Nonrandomized studyPMID 39274317DOIcites ClinicalTrials.gov:NCT06278207